Abstract:Former findings suggested that MTX-based combination therapies show improved efficacy and safety compared to monotherapy[1]. Several studies[2]have been conducted analysis on MTX-based combination therapies, but there is a lack of systematic analysis involving MTX+TCM (Traditional Chinese medicine) therapies.To assess the effectiveness and adverse events of Methotrexate-based (MTX-based) combination therapies(especially MTX + TCM therapies) in rheumatoid arthritis (RA) treatment.A comprehensive search of PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), the Database for Chinese Technical Periodicals and Wanfang data was done without language restriction. A systematic review and network meta-analysis included randomized controlled trials of MTX-based combination therapies and methotrexate monotherapy. The ability of different regimens to reduce rheumatoid factors and inflammatory indicators and the probability of adverse reactions were compared. This study has been registered with PROSPERO under the number CRD42022265799.A total of 37 studies, including 3119 patients, were eligible for inclusion. Meta-analysis results showed that methotrexate combined with other DMARDs or Traditional Chinese Medicine (TCM) could reduce serum Rheumatoid Factor (RF) and C-reactive protein (CRP) levels to some extent, but the therapies combined with TCM were more effective and had a lower rate of adverse effects.The results of RF reducing ability were ranked in ascending order: MTX+LEF+TCM > MTX+SSZ+HCQ > MTX+LEF >MTX+TCM >MTX+HCQ >MTX.While the results of CRP reducing ability were ranked in ascending order: MTX+LEF+TCM>MTX+SSZ+HCQ>MTX+LEF>MTX+TCM>MTX+HCQ.Overall, MTX-based combination therapies are an effective treatment, and the combination of TCM and MTX-based combination therapies is more effective and safer. For treating rheumatoid arthritis or patients with an inadequate response to MTX, MTX-based combination therapies remain an alternative, cost-effective option. To support and validate the potential of TCM and MTX-based combination therapies in treating RA, large-scale, high-quality RCTs should be conducted in the future to provide more accurate and complete data.[1]Bredemeier M, Ranza R, Kakehasi AM.et al.Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil). J Rheumatol. 2022 Jan;49(1):122.[2]Hazlewood GS, Barnabe C, Tomlinson G.et al.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016 Apr 21;353:i1777.None declared.Figure 1.Forest plot of RF reducing ability(A, MTX+SSZ+HCQ; B,MTX+TCM; C,MTX+HCQ; D,MTX+LEF+TCM; E,MTX+LEF; F,MTX)Figure 2.Forest plot of CRP reducing ability(A, MTX+SSZ+HCQ; B,MTX+TCM; C,MTX+HCQ; D,MTX+LEF+TCM; E,MTX+LEF; F,MTX)Figure 3.Forest plot of gastrointestinal adverse events(A, MTX+SSZ+HCQ; B,MTX+TCM; C,MTX+HCQ; D,MTX+LEF+TCM; E,MTX+LEF; F,MTX)None Declared.

Low Dose MTX, HCQ and CTX Can Increase the Expression of GRα Mrna in Vitro

[Effect of Prednisolon, Vincristine and Mitoxantrone on Glucocorticoid Receptor in HL-60 Cell Line].

AB0100 Mtx combined with ctx inhibited il-6 induced jak2-stat3 activation and the induction of p-gp in peripheral blood lymphocytes of rheumatoid arthritis patients

Influence of C677T Polymorphism of 5,10-Methylenetetrahydrofolate Reductase on Methotrexate Toxicity

The effect of various concentration of methrotrexate on the interleukin-17 from peripheral blood mononuclear cells in vitro

The Effect of the Plasma Methotrexate Concentration During High-Dose Methotrexate Therapy in Childhood Acute Lymphoblastic Leukemia.

Low dose methotrexate impaired T cell transmigration through down-regulating CXCR4 expression in rheumatoid arthritis (RA)

Relationship Between Expression Level of Glucocorticoid Receptor and Treatment Outcome in Children with Acute Lymphoblastic Leukemia

Methotrexate Attenuates the Th17/Il-17 Levels in Peripheral Blood Mononuclear Cells from Healthy Individuals and Ra Patients

AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients

Methotrexate inhibits glucocorticoids-induced osteoclastogenesis via activating IFN-{gamma}R/STAT1 pathway in the treatment of rheumatoid arthritis

[Therapeutic Effect and Impact on Cytokine Production by Methotrexate in Rheumatoid Arthritis].

Methotrexate Affects HMGB1 Expression in Rheumatoid Arthritis, and the Downregulation of HMGB1 Prevents Rheumatoid Arthritis Progression

Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.

Single-cell RNA transcriptomic and plasma Lipidomic reveal the potential mechanisms of a Methotrexate-based therapy against Rheumatoid Arthritis

Role of Glucocorticoid Receptor in the Pathogenesis of Systemic Lupus Erythematosus

AB0480 IS TRADITIONAL CHINESE MEDICINE A GOOD OPTION IN METHOTREXATE-BASED COMBINATION THERAPIES IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Clinical Analysis of Chinese Patients With Rheumatoid Arthritis Treated With Leflunomide and Methotrexate Combined With Different Dosages of Glucocorticoid

Combination of Methotrexate and Resveratrol Reduces Pro-Inflammatory Chemokines in Human THP-1 Cells

Signal transduction effect of glucocorticoid receptor in drug resistance of CYP3A5 in leukemia

Astaxanthin Co-treatment with Low Dose Methotrexate Increases the Cell Cycle Arrest and Ameliorates the Methotrexate-induced Inflammatory Response in NALM-6